Australia markets closed

Cellectar Biosciences Inc (NV4.BE)

Berlin - Berlin Delayed price. Currency in EUR
Add to watchlist
2.5200+0.0800 (+3.28%)
At close: 09:40PM CEST
Full screen
Previous close2.3200
Open2.4000
Bid2.4600 x N/A
Ask2.6200 x N/A
Day's range2.4000 - 2.5600
52-week range1.2100 - 3.7000
VolumeN/A
Avg. volume0
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date01 Nov 2023 - 06 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia

    The EMA’s PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment optionsFLORHAM PARK, N.J., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that the European Medicines Agency (EMA) has granted Priority

  • GlobeNewswire

    Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

    Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors Pivotal topline data in Waldenstrom’s macroglobulinemia expected in Q4 2023 with NDA submission and potential product launch in 2024 FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for th

  • GlobeNewswire

    Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update

    FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. Second Quarter and Recent Corporate Highlights In June, the company provided an update for its iopofosine I 131 clinical program and guidance related to its W